...Okay. We'll continue with the next session, which is Xenon Pharmaceuticals. I'm Paul Choi, and I cover the mid-cap biotechnology sector here at the firm. It's my pleasure to have Ian Mortimer to my immediate left here, CEO of Xenon. What we'll do is what we've been doing in other sessions, which is let Ian kick it off with maybe a high-level overview of Xenon, sort of where the company is, its key programs and the overall strategy, and then we'll get into Q&A. Ian Mortimer ...